State Of Wisconsin Investment Board Zentalis Pharmaceuticals, Inc. Transaction History

State Of Wisconsin Investment Board

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$4.09 - $16.13 $3,705 - $14,613	-906 Reduced 2.75%	32,052 $131,000
Q1 2024 May 14, 2024	SELL	$10.83 - $16.49 $46,038 - $70,098	-4,251 Reduced 11.42%	32,958 $519,000
Q4 2023 Feb 12, 2024	SELL	$9.84 - $20.13 $61,509 - $125,832	-6,251 Reduced 14.38%	37,209 $563,000
Q3 2023 Nov 14, 2023	SELL	$19.63 - $28.29 $446,543 - $643,540	-22,748 Reduced 34.36%	43,460 $871,000
Q2 2023 Aug 14, 2023	SELL	$17.41 - $30.05 $239,474 - $413,337	-13,755 Reduced 17.2%	66,208 $1.87 Million
Q1 2023 May 15, 2023	BUY	$16.14 - $24.94 $31,924 - $49,331	1,978 Added 2.54%	79,963 $1.38 Million
Q4 2022 Feb 14, 2023	BUY	$18.07 - $25.6 $578,221 - $819,174	31,999 Added 69.58%	77,985 $1.57 Million
Q3 2022 Nov 14, 2022	SELL	$20.23 - $31.73 $62,409 - $97,887	-3,085 Reduced 6.29%	45,986 $996,000
Q2 2022 Aug 15, 2022	BUY	$17.91 - $52.25 $19,181 - $55,959	1,071 Added 2.23%	49,071 $1.38 Million
Q1 2022 May 13, 2022	SELL	$41.58 - $80.89 $191,268 - $372,094	-4,600 Reduced 8.75%	48,000 $2.22 Million
Q4 2021 Feb 11, 2022	BUY	$66.92 - $84.79 $588,896 - $746,152	8,800 Added 20.09%	52,600 $4.42 Million
Q3 2021 Nov 12, 2021	BUY	$46.83 - $73.5 $238,833 - $374,850	5,100 Added 13.18%	43,800 $2.92 Million
Q1 2021 May 17, 2021	SELL	$35.69 - $52.72 $46,397 - $68,536	-1,300 Reduced 3.25%	38,700 $1.68 Million
Q4 2020 Feb 03, 2021	BUY	$31.71 - $57.97 $745,185 - $1.36 Million	23,500 Added 142.42%	40,000 $2.08 Million
Q2 2020 Aug 12, 2020	BUY	$23.2 - $54.8 $382,800 - $904,200	16,500 New	16,500 $792,000

139

67.9M

48.5K

89.6K

Ticker ZNTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,983,600
Market Cap $99.2M
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...

Get notified when there are updates to the investment portfolio of State Of Wisconsin Investment Board, based on Form 13F filings with the SEC.

Stay updated on State Of Wisconsin Investment Board with notifications on news.